The aim of this study is to present of case of long time survival woman with metastatic breast cancer. The case is a 55- years old female. She underwent left mastectomy with axillary lymphadenectomy for breast cancer. Histological examination showed invasive ductal carcinoma, grade III, estrogen ...
Purpose: We hypothesized different Overall Survival (OS) in metastatic breast cancer (MBC) after relapse vs de novo presentation. Methods: We identified women in British Columbia with MBC diagnosed between 01/2001 and 12/2009. OS from MBC was calculated for relapsed vs de novo cohorts in 3 su...
The median survival of women with metastatic breast cancer (MBC) is 18–24 months, and fewer than 5% are alive and disease free at 5 years. We report toxicity and survival in a cohort of MBC patients receiving high-dose chemotherapy (HDC) with autologous
2013. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 119:1140-1148.Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, et al. Survival in patients with metastatic ...
The reduction in mortality was particularly evident for women with bone metastasis only (multi-adjusted hazard ratio 0.2, 95% CI 0.1 - 0.4; P = 0.001). CONCLUSION In women with metastatic breast cancer at diagnosis, surgical excision of the primary tumor with negative margins significantly ...
Between 1991 and 1995, further 752 and 632 female patients with metastatic breast cancer were extracted respectively from the Connecticut and San Francisco-Oakland registries. The data were analyzed to estimate the 15-year cause-specific survival rates before the year 2005. Results The 5-year ...
Real-world 1-year survival analysis of patients with metastatic breast cancer with liver or lung metastasis treated with eribulin, gemcitabine or capecitabine - ScienceDirectBackground Pooled analyses from 2 phase III trials of patients (pts) with metastatic breast cancer (mBC) treated with eribulin...
community, especially for 10- or 15-year survival./p pMethods/p pBetween 1981 and 1985, 782 and 580 female patients with metastatic breast cancer were extracted respectively from the Connecticut and San Francisco-Oakland registries of the Surveillance, Epidemiology, and End Results (SEER) data...
Thirty-five women with metastatic breast cancer received a battery of baseline psychological tests; results were correlated with length of survival. Patients who died in less than one year from baseline were categorized as short-term survivors, while patients who lived for one year or longer were ...
The investigators say the findings from this meta-analysis add to literature in which "several studies suggest clinical utility" of measuring CTC levels as a means of assessing response status for patients with metastatic breast cancer. Unfortunately, the new study does not show that assessing CTCs...